CD 56-positive acute myeloid leukemia (AML-M 1) with t(16;21) (p11;q22) presenting an extramedullary tumor in the right breast at relapse

A 46-year-old woman was diagnosed as having acute myeloid leukemia (M 1) with translocation t(16;21) (p11;q22). The leukemic cells were positive for CD 13, CD 33, CD 34, CD 41, CD 56 and HLA-DR. After induction chemotherapy, the patient achieved complete remission (CR). However, 8 months later she r...

Full description

Saved in:
Bibliographic Details
Published inRinshō ketsueki Vol. 43; no. 7; p. 560
Main Authors Sato, Etsuko, Takaira, Michiyo, Gohara, Reiko, Araki, Nobuko, Masuoka, Kazuhiro, Imamura, Yutaka
Format Journal Article
LanguageJapanese
Published Japan 01.07.2002
Subjects
Breast Neoplasms - pathology
CD56 Antigen - analysis
Chromosomes, Human, Pair 16
Chromosomes, Human, Pair 21
Female
Humans
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - pathology
Middle Aged
Neoplasm Invasiveness
Translocation, Genetic
Online AccessGet more information

Cover

More Information
Summary:A 46-year-old woman was diagnosed as having acute myeloid leukemia (M 1) with translocation t(16;21) (p11;q22). The leukemic cells were positive for CD 13, CD 33, CD 34, CD 41, CD 56 and HLA-DR. After induction chemotherapy, the patient achieved complete remission (CR). However, 8 months later she relapsed with various additional chromosomal abnormalities. Although the patient achieved a 2nd CR after re-induction chemotherapy, the patient had extramedullary tumors in the right breast twice and relapse occurred frequently. The tumor cells were characterized by the same immunophenotypes and t(16;21) with additional 1 q trisomy. Although there was no evidence of hematological relapse, another type of 1 q trisomy was observed. Furthermore, an increase of abnormalities with 1 q trisomy was noted concomitant with re-increase in the number of blasts. The patient underwent allogeneic bone marrow transplantation (BMT), but she died from BMT complications. The case could have been a karyotype of t(16;21) with additional chromosomal abnormalities through consecutive approaches. Because of the high occurrence rate of relapse, we consider various additional chromosomal abnormalities and the expression of CD 56 as prognostic factors of this condition.
ISSN:0485-1439